There seems to be some confusion here . I lifted this off the...

There seems to be some confusion here . I lifted this off the website for anybody who is interested .
"Solbec managed to take BEC®, a compound that had
gone nowhere between 1990 and 2000 as an anti-cancer agent, and turn it into the
commercially exciting SBP002 over which it could obtain some decent patent protection.
In retrospect it was all relatively simple. SBP002 is a drug made up of two equallyweighted
substances called solamargine and solasonine. They're both triglycoalkaloids,
meaning that in each case three sugar molecules are connected a biologically active
nitrogen-based substance. BEC®, by contrast, was a molecule basically comprised of
one-third solamargine, one-third solasonine and one-third a number of sugary molecules
thrown in for good measure. When Dr Liz Williams, who is a research scientist in UWA’s
Department of Pharmacology and a specialist in structural biology, together with a
number of her UWA colleagues, were testing BEC® on Solbec's behalf, they suggested
to Solbec that just the first two triglycoalkaloids would do the trick and that the other diand
mono-glycosides were extraneous. That advice led to an October 2001
announcement by Solbec in which the company reported that a product made up of just
the two glycoalkaloids was as much as THREE TIMES AS EFFECTIVE in cytotoxicity studies
as BEC®"
One more point , as SBP002 fires up an immune system response against the cancer , it is probably less likely for the tumour to experience rapid growth on completion of treatment , on a tumor where the dug has been effective , than other chemos .
Cheers